文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

膀胱癌诊断与治疗的进展

Advances in Diagnosis and Therapy for Bladder Cancer.

作者信息

Hu Xinzi, Li Guangzhi, Wu Song

机构信息

Institute of Urology, The Affiliated Luohu Hospital of Shenzhen University, Shenzhen University, Shenzhen 518000, China.

Department of Urology, South China Hospital, Health Science Center, Shenzhen University, Shenzhen 518116, China.

出版信息

Cancers (Basel). 2022 Jun 29;14(13):3181. doi: 10.3390/cancers14133181.


DOI:10.3390/cancers14133181
PMID:35804953
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9265007/
Abstract

Bladder cancer (BCa) is one of the most common and expensive urinary system malignancies for its high recurrence and progression rate. In recent years, immense amounts of studies have been carried out to bring a more comprehensive cognition and numerous promising clinic approaches for BCa therapy. The development of innovative enhanced cystoscopy techniques (optical techniques, imaging systems) and tumor biomarkers-based non-invasive urine screening (DNA methylation-based urine test) would dramatically improve the accuracy of tumor detection, reducing the risk of recurrence and progression of BCa. Moreover, intravesical instillation and systemic therapeutic strategies (cocktail therapy, immunotherapy, vaccine therapy, targeted therapy) also provide plentiful measures to break the predicament of BCa. Several exploratory clinical studies, including novel surgical approaches, pharmaceutical compositions, and bladder preservation techniques, emerged continually, which are supposed to be promising candidates for BCa clinical treatment. Here, recent advances and prospects of diagnosis, intravesical or systemic treatment, and novel drug delivery systems for BCa therapy are reviewed in this paper.

摘要

膀胱癌(BCa)是泌尿系统中最常见且治疗费用高昂的恶性肿瘤之一,因其复发率和进展率高。近年来,人们开展了大量研究,以增进对膀胱癌的全面认识,并为其治疗带来众多有前景的临床方法。创新的增强型膀胱镜检查技术(光学技术、成像系统)以及基于肿瘤生物标志物的非侵入性尿液筛查(基于DNA甲基化的尿液检测)的发展,将显著提高肿瘤检测的准确性,降低膀胱癌复发和进展的风险。此外,膀胱内灌注和全身治疗策略(联合疗法、免疫疗法、疫苗疗法、靶向疗法)也为突破膀胱癌的治疗困境提供了丰富的手段。包括新型手术方法、药物组合物和膀胱保留技术在内的多项探索性临床研究不断涌现,有望成为膀胱癌临床治疗的候选方案。本文综述了膀胱癌治疗在诊断、膀胱内或全身治疗以及新型药物递送系统方面的最新进展和前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15c4/9265007/90dc8db33295/cancers-14-03181-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15c4/9265007/44990dd40709/cancers-14-03181-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15c4/9265007/2a5a4d570bff/cancers-14-03181-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15c4/9265007/a311918379d2/cancers-14-03181-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15c4/9265007/6c19923592ea/cancers-14-03181-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15c4/9265007/90dc8db33295/cancers-14-03181-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15c4/9265007/44990dd40709/cancers-14-03181-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15c4/9265007/2a5a4d570bff/cancers-14-03181-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15c4/9265007/a311918379d2/cancers-14-03181-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15c4/9265007/6c19923592ea/cancers-14-03181-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15c4/9265007/90dc8db33295/cancers-14-03181-g005.jpg

相似文献

[1]
Advances in Diagnosis and Therapy for Bladder Cancer.

Cancers (Basel). 2022-6-29

[2]
Recent Progress in Nanomaterial-Based Biosensors and Theranostic Nanomedicine for Bladder Cancer.

Biosensors (Basel). 2023-1-6

[3]
Advances in Liquid Biopsy for Diagnosis of Bladder Cancer.

Int Neurourol J. 2024-6

[4]
A Study of DNA Methylation of Bladder Cancer Biomarkers in the Urine of Patients with Neurogenic Lower Urinary Tract Dysfunction.

Biology (Basel). 2023-8-12

[5]
Raman chemometric urinalysis (Rametrix) as a screen for bladder cancer.

PLoS One. 2020-8-21

[6]
Bladder cancer risk stratification using a urinary mRNA biomarker panel - A path towards cystoscopy triaging.

Urol Oncol. 2021-8

[7]

2015-10

[8]
Efficacy of intra-arterial chemotherapy combined with intravesical chemotherapy in T1G3 bladder cancer when compared with intravesical chemotherapy alone after bladder-sparing surgery: a retrospective study.

World J Urol. 2018-9-6

[9]
Targeting DAD1 gene with CRISPR-Cas9 system transmucosally delivered by fluorinated polylysine nanoparticles for bladder cancer intravesical gene therapy.

Theranostics. 2024

[10]
High and selective cytotoxicity of ex vivo expanded allogeneic human natural killer cells from peripheral blood against bladder cancer: implications for natural killer cell instillation after transurethral resection of bladder tumor.

J Exp Clin Cancer Res. 2024-1-20

引用本文的文献

[1]
IRE1α modulates M1 oncolytic virus sensitivity via ER stress regulation in bladder cancer.

Cancer Drug Resist. 2025-8-13

[2]
SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma.

Future Oncol. 2025-7-29

[3]
Biomarkers for predicting bladder cancer therapy response.

Oncol Res. 2025-2-28

[4]
Epithelioid Angiosarcoma of the Urinary Bladder After Brachytherapy for Prostatic Carcinoma: A Case Report and Literature Review.

Cureus. 2025-1-14

[5]
Mechanistic insights of lenvatinib: enhancing cisplatin sensitivity, inducing apoptosis, and suppressing metastasis in bladder cancer cells through EGFR/ERK/P38/NF-κB signaling inactivation.

Cancer Cell Int. 2025-2-15

[6]
Unveiling urinary extracellular vesicle mRNA signature for early diagnosis and prognosis of bladder cancer.

Theranostics. 2025-1-1

[7]
CDC20 and CCNB1 Overexpression as Prognostic Markers in Bladder Cancer.

Diagnostics (Basel). 2024-12-29

[8]
Epigenetic Biomarkers as a New Diagnostic Tool in Bladder Cancer-From Early Detection to Prognosis.

J Clin Med. 2024-11-26

[9]
Bladder Cancer Treatments in the Age of Personalized Medicine: A Comprehensive Review of Potential Radiosensitivity Biomarkers.

Biomark Insights. 2024-11-6

[10]
Prospective Assessment of VI-RADS with Muscle Invasion in Urinary Bladder Cancer and Its Implication on Re-Resection/Restaging TURBT Patients.

Ann Surg Oncol. 2025-1

本文引用的文献

[1]
Head-to-Head Comparison between High-Resolution Microultrasound Imaging and Multiparametric MRI in Detecting and Local Staging of Bladder Cancer: The BUS-MISS Protocol.

Bladder Cancer. 2022-6-3

[2]
Validation of Vesical Imaging Reporting and Data System score for the diagnosis of muscle-invasive bladder cancer: A prospective cross-sectional study.

Asian J Urol. 2022-10

[3]
Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non-muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker.

Eur Urol Focus. 2022-11

[4]
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.

J Clin Oncol. 2022-6-20

[5]
Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.

Eur Urol. 2022-5

[6]
Advances in Management of Bladder Cancer-The Role of Photodynamic Therapy.

Molecules. 2022-1-23

[7]
From Interferon to Checkpoint Inhibition Therapy-A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC).

Cancers (Basel). 2022-1-29

[8]
The Role of New Technologies in the Diagnosis and Surveillance of Non-Muscle Invasive Bladder Carcinoma: A Prospective, Double-Blinded, Monocentric Study of the XPERT© Bladder Cancer Monitor and Narrow Band Imaging© Cystoscopy.

Cancers (Basel). 2022-1-26

[9]
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.

J Clin Oncol. 2022-4-20

[10]
The impact of grading scheme on non-muscle invasive bladder cancer progression: potential utility of hybrid grading schemes.

Pathology. 2022-6

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索